Introduction
Gene therapy is recognized as a novel method of therapy. The first clinical trial concerning genetic monogenic disorder -severe combined immunodeficiency by retrovirus transfer of normal adenosine deaminase gene to the lymphocytes of patients -was well described. 1 So far, the number of clinical trials has rapidly increased. Cancer, monogenic diseases, vascular and infectious diseases are the main targets of gene therapy. [2] [3] [4] [5] [6] In order to obtain valuable clinical results, sufficient gene transfer is required. The retroviral and adenoviral vectors are the most frequently used in the clinic but very often naked/ plasmid DNA is also useful. [2] [3] [4] 7 Mostly, the therapeutic genes are transferred into the liver, skeletal muscles, heart, central nervous system, lungs, skin, pancreas and blood cells. [2] [3] [4] 7, 8 The therapeutic genes may be administered directly into target tissues or by intravenous or intramuscle injections. [2] [3] [4] 7 There are many expectations associated with gene therapy of vascular diseases resulting from the application of expression vectors encoding angiogenic factors for the treatment of heart or hind limb ischemia. [9] [10] [11] [12] Angiogenic gene therapy is regarded as one of the most promising forms of gene therapy. This method is designed to promote the development of new vessels following gene transfer to the ischemic tissues. The vectors used in angiogenic gene therapy encode angiogenic factors that stimulate the process of new vessel formation, commonly defined as angiogenesis. 13, 14 The main angiogenic genes cloned into expression vectors and used in clinical trials are vascular endothelial factor (VEGF) and fibroblast growth factor (FGF). 15 Among them, the VEGF isoform VEGF165 -the most efficient regulator of angiogenesis in physiology and pathologyplays a crucial role in gene therapy manipulations. The angiogenic signal of VEGF, mediated by tyrosine kinase receptors (VEGFR1 and VEGFR2), promotes proliferation and migration of endothelial cells. 12, [15] [16] [17] [18] [19] Preclinical and clinical trials based on plasmids or viral vectors encoding VEGF have revealed that the genetic constructs stimulate collateral vessel formation, improve blood supply and the clinical state of patients. 10, 12, 15 Apart from vascular diseases, gene therapy based on the manipulations of angiogenesis is also helpful in cancer and sometimes it is the unique method for no-option patients who are not suited to conventional therapies. 20, 21 The main goal in antiangiogenic gene therapy is to stop new vessel formation or to inactivate pre-existing ones. The strategy is based on Folkman's postulate that angiogenesis is essential for the growth of tumors. 22 Since Folkman's observations have been confirmed, it is common knowledge that tumor induces angiogenesis. 22, 23 The factors used in antiangiogenic gene therapy block new vessel formation by various mechanisms. 21, 24, 25 One promising strategy is to use soluble receptors for proangiogenic factors. 26, 27 Experimental data revealed that, for example, the cloned soluble receptor of VEGF (sFLT-1) efficiently blocks VEGFmediated tumor growth and metastasis.
resolved. In angiogenesis-dependent therapies, gene transfer is often based on naked DNA plasmid vectors. 12, 15 Although it requires a large amount of pharmaceutical grade preparations, this type of transfer seems to be quite efficient and well tolerated by patients, and relatively safe. Angiogenic, as well as antiangiogenic, gene therapy offers an optimistic way for the treatment of patients suffering from vascular diseases, including cancer patients. The preliminary trials are very encouraging, although basic scientific research has to still continue.
Principles of angiogenesis
Angiogenic processes are defined as the formation of new vessels. To date, at least three processes contribute to the growth of new blood vessels: angiogenesis, vasculogenesis and arteriogenesis. [30] [31] [32] Angiogenesisformation of new capillary blood vessels from existent microvessels -occurs in physiological and pathological states. It is a multistep process depending on a multitude of angiogenic and antiangiogenic molecules that plays a crucial role in the development of vascular supply in normal tissue, for example, in reproduction and wound healing, as well as in pathology. Inefficient angiogenesis is involved in many ischemic diseases like heart disease, peripheral vascular disease, rheumatoid arthritis, and tumor growth and metastasis. Apart from angiogenesis, vasculogenesis is known as the development of new vessels from blood stem cells and this process is well recognized in embryogenesis. Blood vessels are derived from mesoderm by differentiation of angioblasts. The third known angiogenic process is arteriogenesis, which refers to the formation and modelling of new arteries possessing fully organized tunica media. Often, this process is described as the maturation of pre-existing collaterals.
Angiogenic processes formulate a complex cascade of events, [30] [31] [32] controlled by a multitude of positive and negative regulators (Table 1) . Apart from angiogenic cytokines, many of the extracellular enzymes such as metalloproteinases facilitate angiogenesis by extracellular matrix remodelling. 33, 34 Traditionally, angiogenesis starts with injured tissues (or tumor) that produce and release angiogenic factors that bind to specific receptors located on the endothelial cells of pre-existing blood cells (for VEGF there are VEGFR1, VEGFR2 and VEGFR3 16, 35 ) and activate them to proliferation and migration. The activated endothelial cells migrate to the source of proangiogenic factors (injured tissues, tumor). In the final step, sprouting endothelial cells roll up to organize a blood vessel tube, loops and, finally, matured vessels, stabilized mainly by smooth muscle cells.
Angiogenesis and cancer
In the early 1970s, Folkman described that tumor growth and metastasis formation are tightly dependent on angiogenesis and that tumor vascularization is a process necessary for the progression of cancer from a small, well-localized tumor to a larger neoplastic mass. 22, 36 Adult endothelium is quiescent, but in response to physiological or pathological stimuli like tumors the endothelial cells may start proliferation, migration and organize preliminary vessels. [36] [37] [38] A tumor induces vascular response from host vessels by altering the balance between angiogenic and antiangiogenic factors (Table 1) . Very often, the specific angiogenic switch is postulated for the growth of the tumors. The role of oncogenes like Ras and Raf for angiogenis switch and tumor growth have been the subject of intensive studies. [39] [40] [41] [42] Rak et al 41, 42 postulated that mutations in Ras or Raf are essentially important for tumor angiogenesis. So far, it is acceptable knowledge that a tumor cannot grow without new vessels when they are bigger than a few millimeters in diameter. Consequently, great effort is focused on understanding the processes involved in angiogenesis and many studies concern the evaluation of strategies of antiangiogenic therapy for inhibition of tumor growth and metastasis formation. 20, 24, 25, 43 Folkman's observations led many studies about preventing the angiogenesis process and finding a therapeutic approach. Inhibition of angiogenesis is a promising cancer gene therapy strategy. 25, 42, 44, 45 To date, the number of preclinical and clinical experiments concerning antiangiogenic therapy are essentially increasing. A multitude of endogenous inhibitors of angiogenesis have also been described ( Table 1) and some of them are used in gene therapy. 25 Antiangiogenic therapies have already been proved to be sufficient in a number of experimental models. 25, [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] The inhibitor used possess the ability to suppress tumor growth and limit metastasis. The antiangiogenic gene constructs have also entered clinical trials. 24, 25 These facts were possible because of a few reasons. First of all, side effects associated with the antiangiogenic gene therapy have not been precisely reported. Secondly, antiangiogenic therapy may be effective in a large types of solid tumors because the main target of this strategy are the endothelial cells. Finally, there is no real evidence that cancer develops resistance to this form of therapy. 
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Gene therapy and angiogenesis -rationales
Angiogenesis is a multistep process involved in many physiological and pathological phenomena. The formation of new vessels is postulated to be a crucial point for tumorigenesis and metastasis, whereas deterioration of the arterial system is one of the reasons for ischemic diseases. 20, 23 Therefore, manipulation of angiogenesis in vivo may be a successful gene therapy strategy.
2, 20 In the last decade, significant development of the angiogenic gene therapy methods and applications of various expression vectors encoding angiogenic factors for the treatment of heart or hind limb ischemia has been observed. 20, 59 Preclinical and clinical trials based on plasmids or viral vectors encoding angiogenic cytokines have revealed that the gene preparations stimulate collateral vessel formation, improve blood supply and the clinical state of patients. 14, 15 The second side of the gene manipulations based on angiogenesis is antiangiogenic strategy directly devoted to the treatment of cancer. 24, 25 The inhibition of angiogenesis termed as antiangiogenic gene therapy, seems to be a promising method for cancer therapy. The angiogenesis process observed in tumors may be suppressed by a variety of antiangiogenic factors that limit new vessel formation and/or block the function of mature, existing vessels. 21, 25 Antiangiogenic gene therapy is a very promising method because this strategy is thought to be safe and efficient in in vivo conditions. To date, no serious side effects, toxic effects associated with administration and expression of antiangiogenic factors (usually divided into a few group upon mechanism of action, molecular size or origin) have been reported. Furthermore, antiangiogenic therapy may be useful for a variety of types of tumors because the endothelium and vessels are the main targets for antiangiogenic stimulators. Finally, no resistance to the therapy has been reported. 25, 58 The main expected advantages of antiangiogenic gene therapy are the shrinking of the tumor volume and limiting metastasis formation by the suppression of new vessel formation and/or inhibition of the function of the existing vasculature.
Gene delivery for vascular diseases
Gene therapy has been proposed for the treatment of various diseases including cardiovascular dysfunctions and cancer. Nevertheless, most gene therapy approaches still suffer from very weak efficiency of gene delivery and poor gene expression. The need for efficient vectors seems to be the main obstacle to the successful application of gene therapy in the clinic. 59, 60 The ideal gene therapy vector has numerous features, but mainly it would be injectible, targetable to specific sites, regulatable and able to maintain long-term expression. 61, 62 Apart from that, the ideal vector should be nonimmunogenic (eg vectors with minimal CpG content 63, 64 ), nontoxic, easy and cheap to produce on a large scale. 65, 66 Unfortunately, so far, the ideal vector doesnot exist. Similarly, the cellular fate of the plasmid is not well understood although convincing data are still being published. [67] [68] [69] So far, three possible mechanisms of plasmid uptake are under consideration: large membrane disruption, small membrane pores and receptormediated endocytosis. [67] [68] [69] Generally, gene therapy transfer systems are divided into two groups: viral and nonviral. The nonviral as well as viral delivery systems have visible obstacles and they are under dynamically enlarged evaluation.
2, 59 To date, viral delivery methods are characterized by the highest transfection rates in vivo. The main disadvantage of the plasmid vector seems to be the still relatively low and short efficiency of transfection that is particularly visible in comparison with viral vectors. The experiences, for example with adenoassociated viral vectors demonstrated long-term transgene expression even for over 1 year. 70, 71 Nevertheless, the safety problems with viral vectors seriously limit their large-scale applications. [72] [73] [74] The adeno-associated viral system is a very promising new strategy in angiogenic gene therapy applications for many reasons: rAAV vectors seem to be safer than adenoviruses and retroviruses, they infect both dividing and nondividing cells of broad host range and rAAV vectors may also permit the stable and efficient integration of DNA into the host genome. 75, 76 Many gene therapy experiments have used the rAAV delivery system with significant success. Promising outcomes have been observed in in vitro and in vivo studies. Although many serotypes of AAV are known, the rAAV vectors based on serotype 2 (rAAV2) are the most described and studied. The results demonstrate that rAAV vectors can efficiently transfer therapeutic genes to a number of different cell typesmuscle, liver, neurons, and cancer. Blankinship et al 77 reported that rAAV6 effectively transduced skeletal muscle. Du et al 78 reported that delivery genes to myocardial tissue may be enhanced by AAV serotype 1-specific vectors.
Plasmid preparations production and quality control -general principles
Gene transfer by plasmids may be an efficient method of delivery of angiogenic genes but often requires large amounts of pharmaceutical-grade preparations. 65, 66, [79] [80] [81] Gene preparations very often look like a standard drug product described in classical pharmacology. DNAtherapeutic gene seems to be the active (bulk) substance of the drug and the vector is a carrier of the therapeutic gene. The first steps in the production of clinical grade plasmids are no different from the production of other vectors useful for nonclinical application vectors. 65, 66 Generally, the plasmid preparations are isolated from engineered microorganisms as transformed bacteriaEscherichia coli. In the beginning, the process of isolation is performed under basic conditions (sodium dodecyl sulfate and sodium hydroxide) and for the further efficient purification of plasmids chromatographic methods are often required. 65, 66, 82 It is very important that the clinical product must be manufactured in compliance with GMP in facilities authorized for manufacture by national regulatory agencies. 83 , 84 The quality of the isolated plasmid must be characterized by various biochemical, microbiological, toxicological and pharmacological analyses performed in vitro as well as in vivo. 65, 66, 85, 86 The final plasmid preparations used in gene therapy applications must have well-characterized parameters such as concentration, sequence identity, homology, topology, stability and biodistribution 12 The plasmid DNA delivery system has a number of welldescribed features over viral vectors for use in gene therapy. 87, 88 For example, plasmid vectors are easy to produce and validate on a pharmaceutical scale and they are relatively safe -generally, they do not induce an immunological response. 65, 66, 87, 88 Mainly for these reasons, plasmid vectors very often are chosen for angiogenic gene therapy. 2, 12 It is also worth noting that the plasmid vector delivery method and angiogenic gene therapy are one of the successful clinical gene therapy approaches to date. The naked plasmid DNA effectively transfects the skeletal muscles or heart and successfully expresses angiogenic genes that are due to new vessel formation and the improvement of the clinical state of patients. [67] [68] [69] It is rather common knowledge that naked DNA is expressed in vivo after simple intramuscular injections. [67] [68] [69] However, the efficiency of transfection and expression is still low and still limits larger applications of naked DNA strategy in the clinic. As described by numerous studies, electroporation in vivo technique may be considered as a method that results in increased levels of plasmid transfection in vivo. [89] [90] [91] After electroporation, expression levels of the transgene in muscle increase even 10-fold, but the technical limitations and some side effects such as increased level of creatine kinase in serum limit common use of this method in clinical trials. It is also possible to obtain the effective transfection of skeletal animal muscle after intravascular delivery of naked plasmid DNA, but application of this method in humans leaves a lot to be desired. 92 According to Herweijer and Wolff, 93 clinical gene therapy applications would be simpler if researchers could use naked DNA and forget about using recombinant viruses or complexes of therapeutic DNA with polymers or lipids.
Although it is known that the transfer of angiogenic genes, for example, VEGF or FGF, into ischemic tissues causes the formation of new vessels and improves the clinical state of patients, most current gene therapy approaches are compromised by the inability to deliver the genes efficiently to obtain sustained expression. One of the methods used is the direct injection of naked plasmid DNA into muscles. As Gollins et al 94 reported, the plasmid transgene expression may well persist up to about few weeks in transfected tissues. Authors conclude that efficient gene transfer and its expression are dependent on the vector type. 94 Some studies have shown prolonged expression of plasmids in the skeletal muscle and myocardium. 93 The efficiency of plasmids' transfection can be increased by coupling them with liposomes or inactivated viral particles. [95] [96] [97] Angiogenic gene therapy and vascular diseases -preclinical and clinical evidences Angiogenic gene therapy is regarded as one of the most promising goals of gene therapy. This method is designed to promote the development of new vessels by a gene transfer to the ischemic tissues. Among the growth factors that promote angiogenesis, vascular endothelial growth factor and fibroblast growth factor are the most described and clinically experienced. These factors are also used in gene therapy trials. 98 The angiogenic gene therapy clinical trials in the US are mainly performed with VEGF (64%), Hif 1a/VP16 (14%), FGF (8%) and PDGF (8%). 12 So far, preclinical and clinical studies are focused on the treatment of coronary artery and peripheral artery diseases.
Angiogenic gene therapy of coronary artery disease
Percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass grafting (CABG) and aggressive pharmacological therapy with b-blockers, ACE inhibitors and statins are well known and commonly accepted therapies for treatment of advanced ischemic heart disease. The limited effectiveness of the above-mentioned interventional methods is caused by development of vessel restenoses and graft occlusions. Despite recent advances in the treatment of coronary artery disease, there is still a large number of patients with diffuse coronary atherosclerosis who are not good candidates for standard therapies.
Angiogenic gene therapy may be an alternative or supplemental method to conventional revascularization strategies and may be used with the aim of relieving symptoms, improving quality of life and, hopefully, improving survival, particularly in 'no-option patients'. Before angiogenic factors were used in humans, several animal studies in dogs, rabbits and pigs had been performed. Protein-based angiogenic therapy involves the administration of one or more growth factors. 99, 100 There are no convincing results of studies with angiogenic factors like hepatocyte growth factor, insulin-like growth factor or angiopoetin. 101 Most of the experiments were focused on two cytokines: VEGF and FGF. The cytokines proved to be effective proteins inducing functionally significant angiogenesis confirmed by increased collateral vessel density, improved regional blood flow and higher perfusion pressure. [102] [103] [104] [105] The main disadvantage of the treatment with growth factors is the dose of administered protein. This therapy requires relatively large amounts of angiogenic substance, which increases risk of undesirable angiogenesis promotion in the other tissues. Another problem is of establishing the best route of administration of the growth factors. Several different routes were tested in animal models and various results were obtained according to the technique that was used. The intramuscular route was shown to be the best in a rabbit model of hind limb ischemia. 103 Intracoronary delivery such as continuous infusion or bolus injections improved perfusion and function of ischemic regions. 104, 106 The less effective routes were i.v. and intra-atrial routes because of excessive dilution and pulmonary first-pass uptake. 107 Results obtained from preclinical trials encouraged scientists to introduce angiogenic therapy into clinical practice. Several clinical studies based on administration of angiogenic factors in humans showed quite good effects. The rate of angina symptoms decreased and the 108 The same scientists, Laham et al, 109 conducted a doubleblind, placebo-controlled phase I randomized study with local perivascular delivery of bFGF in 24 patients undergoing coronary bypass surgery. Patients were divided in three groups: placebo, low dose and high dose of bFGF. At 3 months after surgery, there was no improvement in the placebo and low-dose groups, but in the high-dose group, significant resolution of ischemic areas in stress SPECT scans was seen. These findings were confirmed by magnetic resonance imaging. 109 Another study by Schumacher et al 110 has evaluated the phase I clinical randomized trial with the use of FGF-1 and placebo in two groups of patients undergoing incomplete surgical revascularization (20 patients in each group). Direct injection of FGF-1 or placebo, distally to the left internal thoracic artery and to the left anterior descending anastomosis, was performed with the aim of propagating neoangiogenesis. After 3 months, a coronary angiogram revealed capillary formation in the injected portion of the heart in the FGF-1 group when compared with the control group. Despite positive anatomical results, there were no data affecting functional significance of these findings and no information about myocardial perfusion. 110 Results of a phase I doubleblind, placebo-controlled trial with local perivascular delivery of bFGF in ischemic, non revascularizable myocardium in 16 patients undergoing CABG performed by Laham et al 111 showed efficacy of the direct intramyocardial administration of proangiogenic factors in comparison to the control. In 15 of 16 bFGF-treated patients, gradual resolution of stenocardia was observed and in a group of patients treated with a high dose of protein (100 g bFGF) better perfusion was reported even in stress SPECT scans. 111 The study conducted by Hendel et al 112 with human VEGF confirmed the role of a high dose of protein on the final effect of proangiogenic therapy. Four different doses were proposed for the intracoronary infusion in 14 patients. In most of patients, improvement in rest perfusion score occurred but only patients from the high-dose group (0.167 mg/kg) had better rest and stress myocardial perfusion. 112 The first important phase II study was the VIVA trial (the Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis). It was randomized, testing two different doses of VEGF 165 (17 and 50 ng/kg/min) versus placebo. Patients received 20-min intracoronary infusion of the randomized dose and on days 3, 6 and 9, 4 h of i.v. infusion of the same dose. Patients were divided into three groups: 63 patients -placebo, 56 patients -lowdose VEGF 165 and 59 patients -high-dose VEGF 165. They were assessed clinically (angina class and quality of life). Exercise test, rest and stress perfusion imaging were performed at the onset and 2 months and 4 months after the procedure. During the follow-up, there was improvement in quality of life, in angina class in each group and no significant difference in myocardial perfusion between groups 2 months later, but 4 months later the difference between the placebo and VEGF 165 high-dose groups became considerable. In the placebo group, the loss of benefit was noted whereas in the high-dose patients further improvement in angina symptoms and perfusion was observed. 113 The 1-year follow-up showed continued loss of benefit in the placebo group and sustained improvement in angina class in the VEGF 165 group of patients. 114 Presented trials showed that intracoronary infusion and i.v. administration of VEGF 165 is safe and well tolerated. It is worth emphasizing that concealing placebo effect in experimental therapies may be responsible for misinterpretation of clinical outcome.
Preclinical and clinical studies with different growth factors and different routes of administration formed a good basis for the introduction of gene therapy with the aim of augmenting expression of proangiogenic factors in ischemic tissue.
Several animal experiments were conducted in which molecular biology techniques were used to perform transfection of the tissue with genes encoding proteins stimulating angiogenesis. The different vectors have been used to transfect the tissue: RNA, DNA viruses and nonviral vectors (naked DNA, DNA coupled with liposomes). 115, 116 The first animal study in mice that indicated muscle, particularly ischemic muscle, as a highly permissive tissue to the transfer of plasmid DNA was performed by Wolff et al. 117 Then the statement was confirmed in another animal model of hind limb ischemia in the rabbit. The intramuscular transfection of VEGF plasmid resulted in improvement of perfusion in ischemic muscles 2 weeks later. 118 Mack et al, 119 in a porcine model of myocardial ischemia caused by placement of a ameroid constrictor around the circumflex artery, proved that adenoviral vector expressing VEGF 121 induces collateral vessel development and restores nearly normalized myocardial perfusion and function in circumflex distribution in 4 weeks. 119 Results of synergistic administration of FGF-2 and VEGF proteins and its additive effect on induction angiogenesis in vivo in an animal model of rabbit hind limb ischemia presented by Asahara et al 120 gave the basis for the following approach with gene therapy by Kondoh et al 121 who showed that bFGF-induced collateral development exceeded VEGF-induced collateral development and that combined gene delivery of bFGF and VEGF a produced additive or synergistic angiogenic effect as compared with the effects induced by transfer of each gene alone. 121 In other studies, scientists investigated the effect of direct AAV-hVEGF viral vector injection in normal and ischemic mouse myocardium. The model of myocardial ischemia was achieved by ligation of the left anterior descending artery. This approach confirmed that AAV vector can infect efficiently mouse cardiac myocyte, in vitro and in vivo, the gene transfer of hVEGF mediated by AAV-induced angiogenesis in ischemic muscle without angioma formation, but there was no evidence of angiogenesis in non ischemic muscle and finally, no hVEGF was detected in serum samples after the intramyocardial gene transfer had been performed. 122 Results obtained from preclinical studies concerning therapeutic angiogenesis with proteins and gene transfer using viral or nonviral vectors enabled introduction gene therapy into experimental clinical practice.
Angiogenesis-based gene therapy M Malecki et al
The idea of propagation of new vessel formation in ischemic tissue by angiogenic factors was first investigated in patients with serious peripheral artery disease by Isner's group. 123 The evidence of new vessel formation was confirmed 4 weeks after intrarterial administration of plasmid encoding VEGF165 in angiogram and Doppler examination. 123 In 1998, Baugmartner et al 124 presented the results of phase I clinical study with the use of plasmid encoding VEGF165 administered intramuscularly in patients with critical limb ischemia and nonhealing wound. Gene transfection was performed in 10 limbs (nine patients). Evidence of bioavailability of phVEGF165 was documented by an increase in VEGF blood level and bioactivity expressed as an increase in ankle brachial index (ABI). After 10 weeks, in four of seven patients the significant growth of granulation tissue or fully healed wound was noted. In transfected tissue samples, the proliferation of endothelial cells was disclosed. 124 Losordo et al 125 published results of the first randomized clinical phase I trial assessing safety and bioactivity of direct myocardial transfection of plasmid phVEGF165 in patients suffering from symptomatic coronary artery disease. The gene transfer was performed in five patients via minianterior thoracotomy into the viable ischemic muscle. All five patients experienced relief in angina frequency in the second postoperative week. Lower NTG consumption and better quality of life were observed during the follow-up. Objective evidence of reduced ischemia was documented using dobutamine single photon emission computed tomography (SPECT) imaging. Coronary angiography showed improved collateral filling in all patients. This initial study suggests that gene therapy with phVEGF165 as a sole treatment of coronary artery disease is safe and patients benefited from the proposed method. 125 The next report by Rosengart et al 126 summarizes the phase I clinical experience with adenoviral vector expressing VEGF121 cDNA to induce therapeutic angiogenesis in the myocardium of patients with clinically significant coronary artery disease. A total of 21 individuals divided into two groups (group A n ¼ 15-CABG+gene transfer and group B n ¼ 6 -gene therapy via mini access) were enrolled in the study. In both groups, coronary angiography and stress sestamibi scan assessment of wall motion 30 days after therapy suggested improvement in the area of gene administration. All patients reported resolution of angina symptoms and most of the patients from group B had better exercise tolerance. This study revealed that direct administration of adenoviral vector was well tolerated and there was no evidence of systemic immune-related toxicity in any patient. 126 To determine the safety and efficacy of angiogenic gene therapy in our study, Kolsut et al 127 have described the administration of pVEGF165 directly into the myocardium as the single treatment or combined with CABG. VEGF gene transfer was performed in 22 patients (20 males, two females, ages 48 to 73 years old). A 200 mg of the plasmid encoding VEGF165 was injected into the ischemic myocardium, which could not be surgically revascularized in patients undergoing CABG (n ¼ 14), and 400 mg in patients without CABG (n ¼ 8). The value of ejection fraction (EF), myocardial perfusion, angiogram, ventriculography and nitroglycerine consumption as well as quality of life were evaluated pre-and postoperatively. The majority of patients had no complications and no fatal outcome was observed. Two patients developed acute myocardial infarction. Left ventricular function values improved and the majority of patients were free from angina 6 months after surgery.
Patients reported improved quality of life and a reduction in nitroglycerine usage. A reduction in the ischemic defects detected by SPECT was also observed. In some patients, angiography revealed improved collateral filling. 127 Vale et al 128 performed a pilot study to investigate the feasibility and safety of catheter-based myocardial gene transfer of naked plasmid DNA encoding VEGF-2 in six patients with chronic myocardial ischemia. Injections of saline solution of plasmid were guided by NOGA left ventricular electromechanical mapping. Patients with multivessel coronary artery disease, in three or four CCS class, with angina refractory to medical treatment and reversible ischemia on stress SPECT scans were included into the study. EMM performed at 90 days after the procedure disclosed the resolution of ischemic areas of the myocardium that corresponded with improved perfusion scores collected from SPECT rest and pharmacological stress scans in ph VEGF-2 transfected patients. The control group demonstrated no change in the area of ischemia in stress and rest SPECT examination and in EMM. That preliminary clinical experiment suggests feasibility, safety and potential efficacy of the proposed myocardial gene transfer method. 128 The first randomized, double-blind, placebo controlled trial of a potential gene therapy for myocardial angiogenesis was Adenovirus GEN Therapy (AGENT) trial. It was also the first multicenter clinical study with the intracoronary route of delivery Ad5FGF-4. A total of 79 patients with chronic stable angina divided into two groups (n ¼ 19 placebo, n ¼ 60 gene therapy) were enrolled in the trial. Treadmill exercise effect was assessed at 4 and 12 post-treatment weeks. The proportion of patients achieving 430% improvement in exercise treadmill time at week 12 (compared with baseline) was higher in the gene transfer group than in the placebo group, but the difference was not statistically significant. A statistically significant increase was noted in exercise capacity in comparison to the placebo group (27 versus 12%; P ¼ 0.01). The incidence of symptomatic angina or necessity of coronary intervention was lower in the Ad5FGF-4 group versus the placebo group. The AGENT trial proved that Ad5FGF-4 is effective in resolution of ischemia in-patients with chronic coronary artery disease in comparison with placebo. 129 The AGENT 2, trial was designed to evaluate safety and change in stress related reversible myocardial perfusion defect (SPECT) at week 8 in symptomatic patients on maximal pharmacological treatment after Ad5FGF-4 transfection. A total of 52 patients were double-blind randomized and divided into two groups (placebo -17, gene therapy -35). Favorable signals were observed due to gene therapy in comparison with the placebo group. Improved myocardial perfusion, decrease of reversible perfusion defect size in SPECT, lower NTG need and a reduction or complete resolution of angina symptoms were observed in the Ad5FGF-4 group.
Vector distribution was examined in the AGENT trial. Adenovirus could be detected in the pulmonary artery during intracoronary infusion and in peripheral venous Angiogenesis-based gene therapy M Malecki et al blood 1 h later, especially in groups receiving a high dose of viral particles. The level of first-pass extraction by the heart was about 87%. Dose-dependent adverse effects were transient fever in 8%, increase in liver enzymes in 3%, increase in uric acid in 19% and decrease in platelet count in 1%. 129 AGENT and AGENT 2 trials have provided information about safety and early antiischemic effects of Ad5FGF-4 that enabled the launch of large long-term multicenter ongoing AGENT 3 and 4 clinical studies, which will define the optimal dose of viral particle administered during therapy to achieve greatest benefit while taking minimal risk.
Therapeutic angiogenesis is an interesting and exciting new issue in treatment of advanced ischemic heart disease. In the clinic, what still remain unknown are the optimal dose of angiogenic factor, optimal time of its action, the stability of new formed collaterals and their efficiency in time. Another question concerns the best angiogenic factor, combination of several growth factors in one carrier or combination of gene therapy with cellular therapy with the aim of provoking a better angiogenic effect. Our own studies, 130 for example, demonstrated convincingly the efficient induction of new vessels in animals injected with the bicistronic vector encoding two proangiogenic factors -VEGF165 and FGF-2. 130 The proposed system is based upon studies where combined expression of angiogenic cytokines has been used to achieve efficient angiogenesis in vivo. Ibukiyama 131 showed that both exogenous VEGF and FGF can significantly promote collateral vessel development. 131 As was also reported by Whitlock et al, 132 a mixture of different isoforms of VEGF provides a more potent angiogenic response than a single isoform, suggesting that the isoforms may function synergistically. 132 It seems that combined angiogenic therapy can be another effective strategy for the treatment of ischemic disease. It is possible that further development of molecular biology and advances in delivery systems will cause therapeutic angiogenesis to become a supplemental or alternative option to conventional methods of treatment of coronary artery disease.
Angiogenic gene therapy of limb ischemia disease
To date, ischemic disease of the heart and peripheral vessels is still a very serious therapeutic problem. In the case of atherosclerosis, the main cause of ischemia, the major therapeutic goal is the development of collateral circulation. One of the clinical problems is critical limb ischemia (CLI) that is characterized by rest pain and/or tissue necrosis secondary to advanced peripheral arterial disease (PAD). These are observed in patients who have full blockage of main stem arteries, but despite this, they have the ability to walk freely and the claudicating distance is not severe enough to significantly impair their lifestyles. The circulation is improved by a dense net of collaterals, which bring blood to the tissues. Unfortunately, in clinical practice, it is easy to observe patients whose day-to-day living has been significantly impaired by ischemic disease. The progress of changes within the lumen of the vessels leads to critical ischemia, which in turn can cause significant night and rest pain and, eventually, the necrosis of the peripheral tissues. In this group of patients, it is difficult to see enough development of collateral circulation and the only mode of therapy is amputation.
The mechanisms responsible for the development of collateral circulation are not yet fully understood. It is known that the key role in limb neoangiogenesis is played by VEGF, which is a specific endothelial cell mitogen and an inductor of angiogenesis. 133, 134 Apart from VEGF, various angiogenic factors are known and possess potential clinical applications. As was reported by Yamauchi et al, 135 angiopoetin-1 (Ang1) gene administration would be very beneficial for therapeutic angiogenesis in VEGF gene therapy. 135 The preadministration of Ang1 followed by VEGF results in an improvement of hemodynamic status, an increased number of vessels covered with alpha-actin-positive mural cells and prevention of VEGF-mediated edema. 135 Isner et al 136 were the first to propose angiogenic therapy. The first clinical trial involved a 71-year-old female patient with ischemia of the right lower limb. She was injected with 2 mg of the plasmid, which encodes VEGF into the distal part of the popliteal artery. Positive effects of the therapy were already observed after 4 weeks. An increase in the number of collateral vessels on the levels of the knee, shin and ankle was shown through digital subtraction angiography. The next examination after 12 weeks confirmed the development and existence of collaterals. Additionally, intravascular Doppler has shown an increase in the rest and maximal blood flow by, 82 and 72% respectively. The results of therapy with the VEGF plasmid were comparable with the results of therapy with the protein rhVEGF. 136 The only side effects observed in the patient were spider angiomatas and transient, low-grade edema of the ischemic limb. 136 Another group reported a trial of therapy with the plasmid encoding VEGF in a group of six patients with Buerger disease (thromboangitis obliterans). 137 The therapy resulted in the development of a net of collateral circulation shown by digital subtraction angiography. Hemodynamic tests such as the ankle-brachial index (ABI) have confirmed the improvement in circulation as well. In four out of the five patients where the ABI was below 0.5, a net increase of 0.1 was observed. In 2000, a clinical trial involving the treatment of 90 patients with the VEGF-encoding plasmid was reported. In 40 of these patients, VEGF was given intra-arterially and in 50 intramuscularly. 138 Comparative analysis of these two groups has shown the effectiveness of both these methods. Adverse effects were analyzed as well. The edema was not related to the way of administration of the plasmid but rather to the degree of ischemia; the more advanced the ischemia the greater the degree of edema. The results of treatment of lower limb ischemia by angiogenesis stimulation have shown it to be an effective therapy, and the side effects seem to be minor but some potential danger like uncontrolled development of vessels in other tissues or cancer still exists. One of the target organs is the retina. As reported by Ozaki et al, 139 VEGF plays a critical role in the development of vascular networks in the ischemic retina. Diabetic retinopathy and other ischemic retinopathies are potential contraindications for VEGF treatment. Another potential limitation to use of the therapy by way of angiogenic stimulation is the physiology of the development of the atherosclerotic plaque. In his study, Celletti
Angiogenesis-based gene therapy M Malecki et al et al 140 confirmed the effect of rhVEGf injection on the progression and destabilization of the atherosclerotic plaque. The authors report that the effect of VEGF on the atherosclerotic plaque may be proportional to its level in the blood. It was noted that small doses of rhVEGF caused an increase in CD34/FLk-1 expression in the bone marrow. This was not the case when large doses were injected. In addition, VEGF, as a permeability factor, has a profound effect on the intercellular connections in the vascular endothelium. Even a single dose of VEGF causes an increase of the number of macrophages (the 'precursors' of atherosclerotic plaques) in the bone marrow as well as in peripheral blood. In the experiments on animals, 141 a positive effect of the angiogenic stimulation therapy on the levels of mioglobin has been proven. High expression of mioglobin leads to better oxygenation of ischemic muscle tissue, which in turn leads to decrease in symptoms of the disease such as night or rest pains. The observed increase in mioglobin levels was statistically significant (1.5 times what was observed in the control group). The safety problems concerning angiogenic gene therapy were also recently evaluated by Mohler et al. 142 They reported, convincingly data describing the safety of intramuscular delivery of a replication-deficient adenovirus encoding VEGF121 in patients with critical limb ischemia due to PAD. All of the patients tolerated the injection well and there were no serious complications related to the procedure.
Perspectives and summary
Angiogenic and antiangiogenic gene therapy is a new therapeutic approach to the treatment of cardiovascular and cancer patients, respectively. The preliminary data, although very encouraging, need to be well discussed and further study surely continued. It is really possible that further development of molecular biology methods and advances in delivery systems will cause that the therapeutic angiogenesis to become a supplemental or alternative option to the conventional methods of the treatment of angiogenic diseases.
